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Abstract
Objective This study was designed to review the diag-
nostic performance of sentinel node (SN) detection for
assessment of the nodal status in thyroid carcinoma
patients and to determine the technique (using blue dye or
Technetium-99m colloid (99mTc)) that demonstrated the
highest success rate with regard to the detection rate and
sensitivity.
Methods A comprehensive computer literature search of
studies published in English language through December
2007 and regarding SN procedures in patients with thyroid
disorders was performed in MEDLINE. Pooled values
regarding the SN detection rate and the pooled sensitivity
values of the SN procedure were presented with a 95%
confidence interval (CI) for the different SN detection
techniques.
Results Ultimately, we identified 14 studies comprising a
total of 457 patients. Of these, ten studies (n = 329
patients) used the blue dye technique with a pooled SN
detection of 83% (95% CI, 79–87%). The remaining four
studies (n = 128) used 99mTc-colloid with a pooled SN
detection of 96% (95% CI, 91–99%; p \ 0.05 vs. blue dye
technique).
Conclusion In patients with suspected thyroid carcinoma,
SN biopsy demonstrated a higher SN detection rate when
99mTc was used (96%) instead of the blue dye technique
(83%).
Introduction
Lymph node involvement is commonly detected in patients
with thyroid cancer, reportedly up to 70% [1–3]. Further-
more, cervical lymph node metastases are a frequent cause
of recurrent thyroid cancer [4]. However, the prognostic
importance and role of elective lymphadenectomy in
thyroid cancer is controversial. Nodal metastases are a
significant risk factor for survival in patients with thyroid
cancer [3]. Because this risk varies considerably between
different age groups, the prognostic importance and role
of elective lymphadenectomy are controversial. Hence,
knowledge regarding the presence or absence of lymphatic
metastases may be of interest in the staging procedure of
patients with thyroid cancer. Systematic lymphadenectomy
is a standard technique, which is currently used to detect
lymphatic metastatic spread. Alternative techniques,
including resection of macroscopic enlarged nodes, also are
used. Heterogeneity with regard to removal of the lymph
nodes may introduce bias during the staging of thyroid
patients, thereby affecting the predictive value of staging
classification procedures, including the presence of lym-
phatic metastatic spread. Furthermore, this heterogeneity
in the lymph node removal may explain the controversy
regarding the optimal procedure. Certain institutions
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perform routine lymph node dissection, whereas others
refrain from routine dissection.
Recent studies suggested the use of sentinel node (SN)
detection as a less invasive method for studying the lym-
phatic metastatic spread in patients with breast cancer,
melanoma, cervical cancer, and thyroid carcinoma [5–8].
However, considerable variation has been reported
between studies with regard to the success rates of these
SN procedures in patients with thyroid cancer; for example,
Dixon et al. reported SN detection in merely 65% of the
patients, whereas others have reported 100% detection
rates [9, 10]. In a recently concluded meta-analysis
regarding SN detection in patients with cervical cancer, we
observed that the use of radiotracers vs. the blue dye
technique was an important factor that determined the
success rate of SN detection [11].
This review and meta-analysis was designed to deter-
mine whether sentinel lymph nodes (SLNs) can be
identified accurately in patients with thyroid cancer with
the injection of a radiotracer or a blue dye. Furthermore, we
studied the effect of different detection techniques on the
SN detection rate in these patients.
Methods
Study selection
A comprehensive computer literature search of studies
published in English language and comprising human
subjects was performed to identify articles related to the
diagnostic performance of SN and thyroid carcinoma when
compared with histopathological findings used as the ref-
erence standard.
MEDLINE database through December 2007 was sear-
ched for the following terms: ‘‘thyroid neoplasm’’;
‘‘sentinel’’ as the medical subject headings (MeSH). The list
of articles was supplemented by cross-checking the refer-
ence lists containing the identified articles. Review articles,
letters, comments, conference proceedings, unpublished
data, and case reports were excluded from this review.
We included studies that reported SN detection using the
blue dye technique or a radiotracer in patients with sus-
pected thyroid carcinoma. We used the above-mentioned
inclusion and exclusion criteria [12, 13]. In short, only
those studies that satisfied all of the following criteria were
included: 1) minimum sample size of ten included patients;
2) the use of a radioactive tracer and/or blue dye during the
SN procedure; 3) presence of ‘‘gold standard,’’ which was
defined by the use of histopathological evaluation of sur-
gically resected specimens, for sensitivity analysis; and 4)
sufficient data to reassess sensitivity (number of true pos-
itives and false negatives) or the SN detection rate. The
exclusion criterion was an overlap in the patient data
(duplicate publication). In such cases, the more recent
article with most patients was included with an adequate
description of the study population.
Data analyses
The sensitivity of the SN procedure was determined from
the number of true-positive (TP) and false-negative (FN)
results obtained from individual studies. Studies that did not
present patients with tumor-positive SNs were excluded
from statistical pooling for the sensitivity analyses. How-
ever, these studies were included for pooling of the SN
detection rate. Heterogeneities in the sensitivity and SN
detection rate were tested by using the v2 test. Additionally,
we performed subgroup analysis for the different SN
detection techniques: one group comprised studies that used
99mTc-colloid, and another group comprised studies that
used the blue dye technique for SN detection. In the event of
persisting heterogeneity between studies despite the sub-
group analysis, we used the random effect model for
statistical pooling of the data; on the other hand, a fixed
effect model was implemented in the event of homogeneity.
Pooled data are presented with 95% confidence intervals
(CI). Finally, a Z-test was used to compare the pooled
estimates of the values of sensitivity and SN detection rate
obtained from the different SN detection techniques (blue
dye or 99mTc-colloid). P \ 0.05 was considered significant.
Results
Fourteen studies regarding SN were included to assess the
SN detection rate in patients with a suspected thyroid
carcinoma [9, 10, 14–25]. The present review comprised a
total of 457 patients (Table 1). An intratumoral injection
technique was used in the majority of the studies (10 of 14
studies), whereas a peritumoral injection technique was
used in only four studies (Table 2).
There was considerable variance in the histopathological
procedure among the studies included for the analyses. For
example, eight studies mentioned the use of an immuno-
histochemistry (IHC) technique for lymph node evaluation.
Of these, two studies implemented the IHC technique in
the SN only, whereas the remaining studies implemented
IHC in all the lymph nodes. Furthermore, only two studies
described the number of sections or slice thickness pre-
pared during the histopathological analysis.
Based on the technique used for SN detection, the studies
were divided into the following two groups: four studies
(n = 128 patients) used the 99mTc-colloid technique; and
ten studies (n = 329 patients) used the blue dye technique
for the purpose of SN detection. The pooled SN detection
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rate for studies using blue dye was 0.83 (95% CI, 0.79–0.87)
and it was 0.96 (95% CI, 0.91–0.99; p \ 0.05) for studies
using the 99mTc-colloid (Fig. 1). Hence, the difference of
detection rates was reaching a significant level and there
was no overlap of the confidence intervals. Pooling of the
sensitivity was performed for a total of six studies, which
used the blue dye technique for SN detection; the pooled
sensitivity was 0.873 (95% CI, 0.79–0.93). Accordingly, the
false-negative rate was 12.7%. One of the four studies using
99mTc-colloid reported a false-negative rate of 11.3%.
Discussion
The results of this meta-analysis indicate that studies using
the technetium-labeled colloid (99mTc-colloid) technique
yielded an approximately 13% higher SN detection rate
compared with those using the blue dye technique for
SN detection. Hence, detection of SNs in patients with
suspected thyroid carcinoma using a technetium-labeled
colloid may be more effective compared with that obtained
with the use of the blue dye technique. There are little data
regarding the false-negative rate (FNR) for SN detection
with the use of 99mTc-colloid, only one study reported a
FNR of 11.3% [14]. In contrast, the FNR for SN detection
with the use of the blue dye technique was 12.7%. There
was no meta-analysis possible of studies that used a com-
bined technique of both blue dye and 99mTc-colloid.
Presently, the surgical options for patients with thy-
roid carcinoma include total thyroidectomy or unilateral
lobectomy. In addition, lymph node sampling may include
no sampling, blind sampling, node picking of enlarged
lymph nodes, and lymph node dissection. Obviously,
differences in the surgical approaches may result in het-
erogeneity in the tumor classification. SN biopsy is a
minimally invasive approach, and it offers a more stan-
dardized technique of lymph node assessment. Greater
standardization in the evaluation technique renders more
robustness to the prognostic value of lymph node metas-
tasis in thyroid cancer patients. Furthermore, it may prompt
a change in therapy in certain cases. For example, in
institutions using unilateral lobectomy for the surgical
treatment of small papillary thyroid carcinomas, the SN
technique may offer additional prognostic value. Using the
SN technique, it is possible to identify patients with lymph
node metastasis. These patients with small carcinomas and
SN metastasis may require total thyroidectomy followed by
postoperative 131-iodide therapy (I-131 therapy) instead of
unilateral lobectomy without any further treatment.
SN evaluation also might result in an alteration in the
tumor staging of certain patients. Especially, introduction of
the IHC technique for detection of tumor cells in the SNs
might increase the number of patients with lymph node
metastases. With the use of IHC, it is now possible to detect
micrometastases, which would have remained undetected
earlier [26]; thus, a more accurate evaluation regarding the
nodal status can be performed. The detection of microme-
tastases using SNs may enable selection of patients for
further surgery or I-131 therapy; however, it remains to be
seen whether additional treatment, such as I-131, would
improve survival in patients with single SN micrometasta-
sis. More importantly, lymph node metastasis is not
uncommon in patients with small thyroid carcinomas.
Noguchi et al. [3] observed that 69% of the patients with
thyroid lesions measuring \1 cm demonstrated nodal
metastasis. Prospective studies are required to resolve the
Table 1 Patient characteristics of the studies included for the present meta-analysis
Study Year n Male/female
ratio
Mean age
(yr) [range]
Thyroid nodule
(% malignant)
Mean tumor
size (cm) [range]
Dixon et al. [9] 2000 40 5/35 42 [25–75] 33 [1–3.5]
Kelemen et al. [18] 1998 17 3/14 48 [22–68] 71 2 [0.8–4]
Haigh and Giuliano [19] 2000 38 – – 45 –
Arch-Ferrer et al. [20] 2001 22 2/20 37 100 2.5
Takami et al. [21] 2003 68 8/60 42 [22–69] 100 1.9 [0.6–3.9]
Tsugawa et al. [22] 2001 38 8/30 48 [24–72] 100 1.3 [0.5–2.8 ]
Pelizzo et al. [16] 2001 29 8/21 44 [21–86] 100 1.8 [0.5–4]
Chow et al. [23] 2004 15 3/12 54 median [26–71] 100 –
Fukui et al. [24] 2001 22 3/19 53 100 1.3
Dzodic et al. [15] 2006 40 10/30 42 [23–57] 100 1.5 [median]
Sahin et al. [25] 2001 13 – [30–49] 39 –
Stoeckli et al. [10] 2003 10 2/8 50 [20–74] 67 –
Pelizzo et al. [17] 2006 41 12/29 40 [21–68] 98 1.24 [0.5–3 ]
Carcoforo et al. [14] 2007 64 7/57 50 92 0.87
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issue regarding the optimal treatment for patients with small
papillary thyroid carcinoma and lymph node metastasis.
To facilitate a better prediction regarding the outcome
for patients with thyroid cancer, several tumor staging
classifications have been proposed. Furthermore, an accu-
rate staging permits optimal stratification for new clinical
studies. The National Thyroid Cancer Treatment Cooper-
ative Study (NTCTCS) staging classification registration of
1,607 patients was prospectively validated and showed
relatively high accuracy in predicting the outcome of
patients with thyroid cancer [27]. According to this staging
classification, cervical lymph node metastases are of
importance in classifying patients. Patients older than aged
45 years with cervical lymph node metastases were clas-
sified as stage III (high risk), whereas those younger than
aged 45 years and demonstrating cervical lymph node
metastases were considered as stage I (low risk) [27].
There are potential advantages of the SN technique, for
example, reduced morbidity compared with elective lymph
node dissection. Furthermore, it offers a standardized
technique of lymph node evaluation. Although we
reviewed a limited number of studies with a total of 457
patients, it seems that the use of 99mTc-colloid enabled
identification of SN in an additional 13% of the patients
compared with those identified with the blue dye tech-
nique. Hence, for institutions considering the application
of SN detection in patients with thyroid carcinoma, the use
of 99mTc-colloid for SN detection offers a potentially
higher success rate in identifying SN. The use of blue dye
technique for SN detection may be less successful due to
transport of the blue dye to the parathyroid glands.
Considering the results of earlier techniques of SN
detection in patients with melanoma and breast cancer, the
combination of blue dye and 99mTc-colloid might be a
superior alternative. Indeed, Catarci et al. [28] successfully
performed SN detection in all six patients using a combi-
nation of 99mTc-colloid and blue dye. However, more and
larger studies are necessary to assess the potential of the
dual tracer approach in increased SN detection. Because
we did not find any additional evidence regarding this
method in the present literature, we could not perform a
meta-analysis of this method.
Meta-analysis has certain limitations, and publication
bias is a potential confounder. SN studies with negative
results (low detection rates or high FNRs may have a lower
publication rate compared with those with clearly positive
results). Furthermore, the methodological quality varies
amongst studies. For example, only 7 of the 14 studies that
were included in this meta-analysis have reported FNR
data. Future studies reporting SN detection in patients with
thyroid cancer should include FNR data in their results.
The FNR is the single most important quality item for the
SN technique. High numbers of false-negative SN rendersT
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the specific technique unsuitable for routine practice.
Indeed, the pooled value of the FNR of six studies that
used blue dye is higher compared with those that included
patients with breast cancer or melanoma. Hence, further
improvements in the SN technique for patients with
thyroid carcinoma should be considered before a routine
application is established. Future studies should investigate
demographic data and data regarding the tumor size should
be included to study any potential population differences.
Finally, future studies should carefully report the histopa-
thological methods used. It is relatively simple to obtain
these data, such as the number of sections through the SN;
however, they are lacking in the majority of the studies.
Conclusions
Our findings indicate that SN detection is possible in
patients with thyroid cancer. The use of 99mTc-colloid
enables SN identification in 96% of the patients. However,
the use of blue dye technique is probably associated with a
lower SN detection rate compared with that obtained by the
99mTc-colloid technique.
The theoretical advantages of the SN technique require
further probing through clinical studies. Furthermore, more
studies are required to identify the optimal SN detection
technique, especially with regard to the FNR. Additionally,
the clinical impact of SN detection with regard to the
prognosis and treatment requires further attention in new
clinical studies.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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